<DOC>
	<DOCNO>NCT01079013</DOCNO>
	<brief_summary>The study hypotheses introduction dose escalate treosulfan , substitution busulfan melphalan , reduce toxicity allogeneic transplantation improve disease eradication patient lymphoid malignancy eligible standard transplantation .</brief_summary>
	<brief_title>Treosulfan-based Conditioning Allogeneic Stem-cell Transplantation ( SCT ) Lymphoid Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Treosulfan</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>1 . Age less physiologic 68 year . 2 . Patients NHL HL indication allogeneic transplantation follow : Aggressive lymphoma Hodgkin lymphoma ; relapse autologous transplant Follicular lymphoma ; failure least one prior regimen 3 . Disease must chemosensitive stable status prior therapy transplant . 4 . Patients must HLA match related unrelated donor willing donate either peripheral blood stem cell bone marrow . Matching base highresolution class I ( HLAA , B , C ) class II ( HLADRB1 , DQB1 ) typing . The goal transplant &gt; 3 x 106 CD34+ cell per kg body weight recipient 5 . Patients must sign write informed consent 6 . Adequate birth control fertile patient 1 . Overt progressive disease prior transplantation . 2 . Bilirubin &gt; 3.0 mg/dl , transaminases &gt; 3 time upper normal limit 3 . Creatinine &gt; 2.0 mg/dl 4 . ECOGPerformance status &gt; 2 5 . Uncontrolled infection 6 . Pregnancy lactation 7 . Abnormal lung diffusion capacity ( DLCO &lt; 40 % predict ) 8 . Severe cardiovascular disease 9 . CNS disease involvement 10 . Pleural effusion ascites &gt; 1 liter 11 . Known hypersensitivity fludarabine treosulfan 12 . Psychiatric conditions/disease impair ability give inform consent adequately cooperate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>